Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Ultragenyx Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: On July 9, 2025, Ultragenyx issued a press release announcing the randomized controlled portion of the Phase 3 Orbit Study for Osteogenesis Imperfecta is progressing toward final analysts for end of year but stopped short of presenting any interim results. Ultragenyx had “hoped to be able to stop the study early” if positive results were achieved at the interim analysis. Following this news, Ultragenyx’s stock price fell by $10.83 per share to open at $30.61 per share.
In order to be eligible to join the RARE class action lawsuit, you must have incurred a loss on shares of Ultragenyx Pharmaceutical Inc. purchased during the class period listed above.
TOP
